Clinical trials: Metastatic Prostate Cancer
Metastatic Cancer, Prostate Cancer
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for prostate cancer.
- Trial name
- NCT00002503
- Testing
- strontium chloride Sr 89
- Where
- 21 sites in Belgium, Denmark and 7 more
- Volunteers
- 204 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer
RATIONALE: High-intensity focused ultrasound ablation uses high-energy sound waves to kill tumor cells. PURPOSE: This phase II trial is studying the side effects of high-intensity focused ultrasound ablation and to see how well…
- Trial name
- NCT00987675
- Testing
- pharmacological study, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College London Hospitals
Bone Cancer, Bone Tumor
A Dose Finding Study to Treat Bone Tumor(s)
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects…
- Conditions
- Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone
- Trial name
- NCT06008483
- Testing
- 153-Sm-DOTMP (Samarium-153-DOTMP)
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- QSAM Therapeutics, Inc.
Prostate Cancer Metastatic Castration-Resistant
External Beam and Radioligand Radiotherapy for mCRPC
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer.
- Trial name
- ARREST (NCT07354594)
- Testing
- External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy, Standard of care 177Lutetium-PSMA
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
The goal of this clinical research study is to find the highest safe dose of docetaxel in combination with Gleevec (imatinib mesylate) that can be given to men with advanced androgen-independent metastatic prostate cancer that…
- Trial name
- NCT00038194
- Testing
- imatinib mesylate, docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate…
- Trial name
- NCT07428642
- Testing
- Androgen Deprivation Therapy, Apalutamide, Enzalutamide
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT05398302
- Testing
- Image Guided Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer Metastatic
Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry.
- Trial name
- ANCHORProstate (NCT05457699)
- Testing
- Metastasis directed radiotherapy (MDRT), no MDRT
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer (Diagnosis), Prostate Cancer Metastatic
Evaluation of the Metastasis and Recurrence of Prostate Cancer
This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging methods (whole body bone scintigraphy and…
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Metastatic, Prostate Cancer Recurrent, Prostate Cancer Stage
- Trial name
- NCT03507595
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
This phase II trial tests how well re-treatment with 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic), that…
- Trial name
- NCT06288113
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Prostate Carcinoma
Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223…
- Trial name
- NCT03011749
- Testing
- FLT PET/CT
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC